Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q14392
UPID:
LRC32_HUMAN
Alternative names:
Garpin; Glycoprotein A repetitions predominant; Leucine-rich repeat-containing protein 32
Alternative UPACC:
Q14392; Q86V06
Background:
Transforming growth factor beta activator LRRC32, also known as Garpin, Glycoprotein A repetitions predominant, and Leucine-rich repeat-containing protein 32, is a pivotal regulator of transforming growth factor beta (TGF-beta). It maintains TGF-beta in a latent state, controlling its activation and ensuring proper storage in the extracellular space. This protein is essential for the regulation of TGF-beta activation through integrin-dependent mechanisms and plays a crucial role in immune regulation and developmental processes.
Therapeutic significance:
The protein's involvement in cleft palate, proliferative retinopathy, and developmental delay highlights its therapeutic significance. Understanding the role of Transforming growth factor beta activator LRRC32 could open doors to potential therapeutic strategies for these conditions, offering hope for targeted interventions.